Year: 2026
Type: article
Study design: Observational Study
Abstract: Background and Objectives: Spinocerebellar ataxias are genetically heterogeneous neurodegenerative disorders characterized by progressive cerebellar degeneration. Among them, SCA7 and SCA8 are particularly rare, and their longitudinal natural history has not been well defined. Using data from the Clinical Research Consortium for the Study of Cerebellar Ataxias, we examined disease progression in genetically confirmed SCA7 and SCA8 patients in North America. Methods: Longitudinal changes in motor severity were assessed using the Scale for the Assessment and Rating of Ataxia (SARA), alongside cognitive function (Cerebellar Cognitive Affective Syndrome scale [CCAS]) and depressive symptoms (Patient Health Questionnaire-9 (PHQ-9)), applying linear mixed-effects models with genetic and clinical covariates. Our cohort included 27 individuals with SCA7 and 51 with SCA8 with baseline data, among which 22 individuals with SCA7 and 42 with SCA8 have longitudinal follow-up. Results: = 0.28). Longitudinal analyses demonstrated that SCA7 progressed relatively rapidly, with SARA scores worsening by 1.68 points per year, while SCA8 showed substantially slower progression at 0.47 points per year. In both disorders, progression was predominantly driven by deterioration in the axial SARA domain, particularly gait and stance. In contrast, CCAS and PHQ-9 scores remained stable over approximately 5 years of follow-up, with no significant longitudinal changes detected. Discussion: These findings demonstrate distinct disease trajectories between SCA7 and SCA8 to inform future longitudinal studies and therapeutic trials.
Source: Neurology Genetics
Authors: Yi-Cheng Lin, Nadia Amokrane, Sandie Worley, Nankai Wang, Lauren Moore, Andrew Rosen, Laura P. Crespo, Kelsey Trace, Tetsuo Ashizawa, Andrew Billnitzer, Susan L. Perlman, Fisher Aaron, Khalaf O. Bushara, Michael D. Geschwind, Cameron Dietiker, Christopher M. Gomez, Mahesh Padmanaban, Puneet Opal, Rizwan S. Akhtar, Henry L. Paulson, Sharan Ram Srinivasan, Peter K. Todd, Frank Ferrari, Chiadi U. Onyike, Ann Fishman, Sarah Ying, Ashley M. Paul, Jeremy D. Schmahmann, Christopher D. Stephen, Anoopum S. Gupta, Chih-Chun Lin, S.H. Subramony, Matthew Robert Burns, George R. Wilmot, Antoine Duquette, Theresa Ann Zesiewicz, Marie Y. Davis, Ali G. Hamedani, Joaquin A. Vizcarra, Stefan M. Pulst, Sharon Primeaux, Melissa Wolfe Beiner, Laura Ruggiero, Christian Rummey, Vikram G. Shakkottai, Liana S. Rosenthal, Sheng-Han Kuo
Institutions: Columbia University Irving Medical Center, Chang Gung University, National Ataxia Foundation, Houston Methodist Research Institute, University of California, Los Angeles, University of Minnesota, University of California, San Francisco, University of Chicago, Northwestern University, University of Michigan, Johns Hopkins University, Johns Hopkins Medicine, Harvard University, Massachusetts General Hospital, University of Florida, Emory University, Centre Hospitalier de l’Université de Montréal, Université de Montréal, University of South Florida, University of Washington, University of Pennsylvania, University of Utah, The University of Texas Southwestern Medical Center, Biohaven Pharmaceuticals (United States)
Language: English
Subfield: Cellular and Molecular Neuroscience
Field: Neuroscience
Domain: Life Sciences
Keywords: spinocerebellar ataxia type 7, spinocerebellar ataxia type 8, disease progression, natural history (disease), cerebellar degeneration, age of onset, trinucleotide repeat expansion, Scale for the Assessment and Rating of Ataxia, cerebellar cognitive affective syndrome, depressive symptoms, genetic heterogeneity
Open Access status: gold
Estimated APC paid: $3,300
OpenAlex ID: W7235238756
